Mina N. Dinh

Mina N. Dinh

Auto-generated profile, based on publicly available information

Mina N. Dinh

Cleveland Clinic Foundation, Translational Hematology and Oncology Research Division

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in Science Advances
Verified
Journal Article
Open access
NFNathan Farrokhian
Nathan Farrokhian
JMJeff Maltas
Jeff Maltas
MDMina Dinh
Mina Dinh
ADArda Durmaz
Arda Durmaz
PEPatrick Ellsworth
Patrick Ellsworth
JSJacob G Scott
Jacob G Scott
In this study, we experimentally measure the frequency-dependent interactions between a gefitinib-resistant non–small cell lung cancer population and its sensitive ancestor via the evolutionary game assay. We show that cost of resistance is insufficient to accurately predict competitive exclusion and that frequency-dependent growth rate measurements are required. Using frequency-dependent growth rate data, we then show that gefitinib treatment results in competitive exclusion of the ancestor, while the absence of treatment results in a likely, but not guaranteed, exclusion of the resistant strain. Then, using simulations, we demonstrate that incorporating ecological growth effects can influence the predicted extinction time. In addition, we show that higher drug concentrations may not lead to the optimal reduction in tumor burden. Together, these results highlight the potential importance of frequency-dependent growth rate data for understanding competing populations, both in the laboratory and as we translate adaptive therapy regimens to the clinic.

30 October 2024 in MethodsX
Verified
Journal Article
Open access
MDMina N. Dinh
Mina N. Dinh
MHMasahiro Hitomi
Masahiro Hitomi
ZAZahraa A. Al-Turaihi
Zahraa A. Al-Turaihi
JSJacob G Scott
Jacob G Scott
Alamar Blue (AB) has become an increasingly popular reagent of choice for cell viability assays. We chose AB over other reagents such as MTT and Cell-Titer Glo due to its cost effectiveness and its ability to be a nondestructive assay. While analyzing the effect of osimertinib, an EGFR inhibitor on the non-small cell lung cancer cell line, PC-9, we noticed unexpected right-shifts of dose response curves as compared to the curves obtained by Cell Titer Glo assay. Here, we describe our modified AB assay method to avoid that right shift in dose response curves. • Removal of the drug containing medium prior to AB addition eliminated the falsely increased readings, giving comparable dose response curves as determined by Cell Titer Glo assay. • Plate-to-plate variability can be minimized by adding an appropriate concentration of a common fluorescence calibration standard to the assay plates to calibrate fluorimeter sensitivity. • Alamar Blue can be used as a continuous longitudinal assay to monitor cell growth or recovery from drug toxicity over time.

19 March 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
MDMina N. Dinh
Mina N. Dinh
MHMasahiro Hitomi
Masahiro Hitomi
ZAZahraa A. Al-Turaihi
Zahraa A. Al-Turaihi
JSJacob G Scott
Jacob G Scott
Alamar Blue (AB) has become an increasingly popular reagent of choice for cell viability assays. We chose AB over other reagents such as MTT and Cell-Titer Glo due to its cost effectiveness and its ability to be a nondestructive assay. While analyzing the effect of osimertinib, an EGFR inhibitor on the non-small cell lung cancer cell line, PC-9, we noticed unexpected right-shifts of dose response curves as compared to the curve obtained by Cell Titer Glo assay. Here, we describe our modified AB assay method to avoid right shift right shift in dose response curve. Unlike some of the redox drugs that were reported to directly affected AB reading, osimertinib itself did not directly increase AB reading. Yet, the removal of the drug containing medium prior to AB addition eliminated falsely increased reading giving comparable dose response curve as the one determined by Cell Titer Glo assay. When a panel of 11 drugs were assessed, we found that this modified AB assay eliminated unexpected similar right shifts detected in other epidermal growth factor receptor (EGFR) inhibitors. We also found that plate-to-plate variability can be minimized by adding an appropriate concentration of rhodamine B solution to the assay plates to calibrate fluorimeter sensitivity. This calibration method also enables a continuous longitudinal assay to monitor cell growth or recovery from drug toxicity over time. Our new modified AB assay is expected to provide accurate in vitro measurement of EGFR targeted therapies.

2 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
PSPaulameena V. Shultes
Paulameena V. Shultes
DTDagim S. Tadele
Dagim S. Tadele
ADArda Durmaz
Arda Durmaz
DWDavis T. Weaver
Davis T. Weaver
RBRowan Barker-Clarke
Rowan Barker-Clarke
JSJacob G Scott
Jacob G Scott
Cell-cell fusion has been implicated in various physiological and pathological processes, including cancer progression. This study investigated the role of cell-cell fusion in non-small cell lung cancer (NSCLC), focusing on its contribution to chemoresistance and tumor evolution. By co-culturing drug-sensitive and drug-resistant NSCLC cell lines, we observed spontaneous cell-cell fusion events, particularly under gefitinib selection. These fused cells exhibited enhanced fitness and a higher degree of chemoresistance compared to parental lines across a panel of 12 chemotherapeutic agents. Further analysis, including fluorescence imaging and cell cycle analysis, confirmed nuclear fusion and increased DNA content in the fused cells. Bulk RNA sequencing revealed genomic heterogeneity in fused cells, including enrichment of gene sets associated with cell cycle progression and epithelial-mesenchymal transition, both of which are hallmarks of cancer. These findings demonstrate that cell-cell fusion can act as a novel source of chemotherapeutic resistance and further promote aggressive phenotypes in NSCLC, highlighting the potential of fusion as a therapeutic target.

29 October 2026 in EcoEvoRxiv
Verified
Preprint
Open access
PDF file
MDMina Dinh
Mina Dinh
JÅJ. Arvid Ågren
J. Arvid Ågren
JIJarrell Imamura
Jarrell Imamura
KLKristi Lin-Rahardja
Kristi Lin-Rahardja
JWJinling Wu
Jinling Wu
JSJacob Scott
Jacob Scott
Evolutionary processes are inherently stochastic, such that independently evolving populations exposed to identical conditions may not follow identical trajectories. In cancer, this stochasticity contributes to diverse resistance pathways in tumor cell populations exposed to the same therapeutic pressures. Experimental evolution provides a controlled framework for studying these dynamics by exposing cells to sustained drug treatment and allowing resistance to evolve over time. While powerful, insufficient documentation of experimental design can obscure biologically meaningful stochasticity and hinder comparisons across studies. Here, we argue for the importance of rigorous experimental design and transparent reporting in cancer experimental evolution. We describe eight key factors that should be considered when designing an experimental evolution study: (1) choosing a model system, (2) methodology for tracking evolution, (3) defining evolutionary replicates, (4) selecting treatment dose, (5) determining initial seeding density, (6) defining evolutionary cycles, (7) selecting experiments to perform at each cycle, and (8) deciding when to end the experiment. Careful consideration of these factors improves repeatability and facilitates identification of deterministic and contingent features of resistance evolution. For cancer biologists, these design choices determine whether resistance mechanisms, collateral sensitivities, persister states, and clinically actionable vulnerabilities can be interpreted as reproducible biology rather than protocol-specific artifacts.